Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study.
glioblastoma
reoperation timing
treatment strategy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
14
02
2023
revised:
14
04
2023
accepted:
24
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Glioblastoma inevitably recurs, but no standard regimen has been established for treating this recurrent disease. Several reports claim that reoperative surgery can improve survival, but the effects of reoperation timing on survival have rarely been investigated. We, therefore, evaluated the relationship between reoperation timing and survival in recurrent GBM. A consecutive cohort of unselected patients (real-world data) from three neuro-oncology cancer centers was analyzed (a total of 109 patients). All patients underwent initial maximal safe resection followed by treatment according to the Stupp protocol. Those meeting the following criteria during progression were indicated for reoperation and were further analyzed in this study: (1) The tumor volume increased by >20-30% or a tumor was rediscovered after radiological disappearance; (2) The patient's clinical status was satisfactory (KS ≥ 70% and PS WHO ≤ gr. 2); (3) The tumor was localized without multifocality; (4) The minimum expected tumor volume reduction was above 80%. A univariate Cox regression analysis of postsurgical survival (PSS) revealed a statistically significant effect of reoperation on PSS from a threshold of 16 months after the first surgery. Cox regression models that stratified the Karnofsky score with age adjustment confirmed a statistically significant improvement in PSS for time-to-progression (TTP) thresholds of 22 and 24 months. The patient groups exhibiting the first recurrence at 22 and 24 months had better survival rates than those exhibiting earlier recurrences. For the 22-month group, the HR was 0.5 with a 95% CI of (0.27, 0.96) and a
Identifiants
pubmed: 37173996
pii: cancers15092530
doi: 10.3390/cancers15092530
pmc: PMC10177480
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Health of the Czech Republic
ID : grant NU21-03-00195
Organisme : Ministry of Health of the Czech Republic
ID : conceptual development of research organization - FNOL, 00098892
Organisme : Ministry of Health of the Czech Republic
ID : conceptual development of research organization - MMCI, 00209805
Organisme : Ministry of Health of the Czech Republic
ID : conceptual development of research organization - FNB, 65269705
Organisme : Ministry of Health of the Czech Republic
ID : grant NU20-03-00148
Organisme : Ministry of Health of the Czech Republic
ID : conceptual development of research organization - FNUSA, 00159816
Références
Curr Oncol. 2021 Mar 21;28(2):1280-1293
pubmed: 33801093
J Neurooncol. 2018 Apr;137(2):409-415
pubmed: 29294233
Oncology. 2017;93(1):43-50
pubmed: 28395288
Front Neurol. 2019 Mar 26;10:286
pubmed: 30984099
Neuro Oncol. 2013 Jul;15(7):930-5
pubmed: 23553268
Neurologist. 2022 May 01;27(3):119-124
pubmed: 34855660
Appl Immunohistochem Mol Morphol. 2022 Mar 1;30(3):178-183
pubmed: 35262523
J Neurooncol. 2017 May;132(3):419-426
pubmed: 28374095
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
J Neurooncol. 2017 Sep;134(2):377-385
pubmed: 28685404
J Neurooncol. 2014 Oct;120(1):117-23
pubmed: 25012955
World Neurosurg. 2018 Jul;115:453-459.e3
pubmed: 29654958
World Neurosurg. 2012 Dec;78(6):658-69
pubmed: 22484078
J Neurooncol. 2017 Feb;131(3):585-591
pubmed: 27844310
Neurol Sci. 2015 Aug;36(8):1431-40
pubmed: 25805705
Cancer. 2012 Apr 15;118(8):2163-72
pubmed: 21882183
Neurosurg Focus. 2015 Mar;38(3):E11
pubmed: 25727220
J Neurosurg Sci. 2017 Jun;61(3):233-244
pubmed: 26149222
Medicine (Baltimore). 2017 Dec;96(49):e9053
pubmed: 29245310
Neuro Oncol. 2012 Dec;14(12):1503-10
pubmed: 23090987
Neurosurg Rev. 2007 Jan;30(1):56-61; discussion 61-2
pubmed: 17119901
Pathol Oncol Res. 2019 Jul;25(3):971-978
pubmed: 29556922
World Neurosurg. 2017 Dec;108:610-617
pubmed: 28939537
J Neurosurg. 2018 Nov 1;129(5):1231-1239
pubmed: 29303449
J Neurooncol. 2017 Nov;135(2):285-297
pubmed: 28726173
Diagnostics (Basel). 2020 Sep 05;10(9):
pubmed: 32899528
J Clin Oncol. 1983 Nov;1(11):710-9
pubmed: 6668489
Neuro Oncol. 2013 Aug;15(8):1096-101
pubmed: 23800677
Front Oncol. 2015 May 15;5:106
pubmed: 26029663
Neuro Oncol. 2009 Dec;11(6):842-52
pubmed: 19229057
J Neurooncol. 2019 May;142(3):489-497
pubmed: 30783874
Neuro Oncol. 2016 Apr;18(4):549-56
pubmed: 26823503
Front Oncol. 2020 Jul 03;10:840
pubmed: 32719739
J Neurosurg. 2014 Oct;121(4):802-9
pubmed: 25061868
J Clin Epidemiol. 2008 Dec;61(12):1216-1221
pubmed: 18619803
Cancers (Basel). 2022 Nov 09;14(22):
pubmed: 36428604
Neurooncol Adv. 2022 Jun 04;4(1):vdac075
pubmed: 35769410
J Neurooncol. 2016 Nov;130(2):269-282
pubmed: 27174197
J Neurosurg. 2009 Jan;110(1):156-62
pubmed: 18847342
Acta Neurol Scand. 2017 Sep;136(3):239-245
pubmed: 28025828
Neurol Med Chir (Tokyo). 2017 Jan 15;57(1):17-27
pubmed: 27725524
J Clin Oncol. 2023 Feb 20;41(6):1285-1295
pubmed: 36260832
World Neurosurg. 2018 May;113:e179-e189
pubmed: 29427817
J Clin Oncol. 2010 Aug 20;28(24):3838-43
pubmed: 20644085
Neuro Oncol. 2014 May;16(5):719-27
pubmed: 24463354
Neuro Oncol. 2014 Sep;16(9):1255-62
pubmed: 24670608
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Neurosurg. 2017 Jun;126(6):2045-2050
pubmed: 28430037
Acta Neuropathol. 2022 Dec;144(6):1127-1142
pubmed: 36178522
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
J Clin Neurosci. 2016 Feb;24:105-11
pubmed: 26671314
J Neurooncol. 2017 Apr;132(2):249-254
pubmed: 28101701
J Neurosurg. 2016 Apr;124(4):977-88
pubmed: 26495941
Neuro Oncol. 2013 Feb;15(2):242-50
pubmed: 23243055
J Neurooncol. 2019 Apr;142(2):327-335
pubmed: 30659523
J Neurooncol. 2012 May;108(1):89-97
pubmed: 22307805
Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
pubmed: 18496181
J Neurooncol. 2008 May;88(1):105-13
pubmed: 18283418
J Neurosurg. 2013 Apr;118(4):812-20
pubmed: 23082884
J Neurosurg. 2021 Dec 31;:1-11
pubmed: 34972087
J Neurooncol. 2013 Jan;111(2):177-85
pubmed: 23264191
Front Neurol. 2019 Jan 31;10:42
pubmed: 30766509
Curr Treat Options Oncol. 2019 Jul 19;20(9):71
pubmed: 31324990
Onco Targets Ther. 2014 Mar 24;7:485-90
pubmed: 24711705
J Neurooncol. 2017 Aug;134(1):169-175
pubmed: 28547592
J Neurooncol. 2017 Aug;134(1):213-219
pubmed: 28567589
J Neurosurg. 2011 Mar;114(3):613-23
pubmed: 20397896
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Biomedicines. 2022 Aug 09;10(8):
pubmed: 36009473
Radiat Oncol. 2013 Sep 25;8:222
pubmed: 24066926
Am J Clin Oncol. 2019 May;42(5):481-486
pubmed: 30973372
Acta Neurochir (Wien). 2022 Feb;164(2):429-438
pubmed: 33052493
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Clin Transl Oncol. 2019 May;21(5):582-587
pubmed: 30284233
AJNR Am J Neuroradiol. 2016 Dec;37(12):2224-2230
pubmed: 27609621
Turk Neurosurg. 2010 Apr;20(2):117-25
pubmed: 20401838
Neuro Oncol. 2011 Oct;13(10):1118-24
pubmed: 21813511
Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
pubmed: 18425006
Acta Neurochir (Wien). 2022 Aug;164(8):1985-1993
pubmed: 35397674
BMC Cancer. 2016 Nov 22;16(1):914
pubmed: 27876012
Radiat Oncol. 2021 Feb 18;16(1):36
pubmed: 33602305
Case Rep Neurol. 2016 Jan 08;8(1):1-9
pubmed: 26889149
World Neurosurg. 2022 Oct;166:e624-e631
pubmed: 35870781
CNS Oncol. 2017 Jul;6(3):185-193
pubmed: 28399638
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
Anticancer Drugs. 2016 Feb;27(2):133-7
pubmed: 26574999
J Clin Oncol. 2014 Mar 10;32(8):774-82
pubmed: 24516010
CNS Oncol. 2014 Jul;3(4):257-65
pubmed: 25286037
J Neurosurg. 2019 Mar 01;132(3):895-901
pubmed: 30835701
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
BMJ Open. 2013 Mar 15;3(3):
pubmed: 23503605